Skip to content

Study · Non-randomized trial · 2020

8 results

Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity.

Iacobellis G, Villasante Fricke AC

Journal of the Endocrine Society13 Mar 2020Cited by 127 (Europe PMC)

PMID32190806 (opens in a new tab)PMCIDPMC7069837 (opens in a new tab)DOI10.1210/jendso/bvz042 (opens in a new tab)PepBankPUB-32190806
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with T2DM and obesity, epicardial fat thickness decreased from baseline after 12 weeks of semaglutide, a reduction of about 20% reported for the semaglutide and dulaglutide groups together.

    In plain wordsIn patients with diabetes and obesity, fat thickness around the heart fell from baseline with semaglutide, about 20% across both drug groups.

    Peptide
    Semaglutide
    Outcome
    DecreaseEpicardial fat thickness
    Study

    n: not reported in source

    Outcome group
    Body composition · Cardiovascular
    Studied dose
    up to 1 mg weekly · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    Epicardial adipose tissue thickness reduction
    20%
    semaglutide and dulaglutide groups, as reported

    Source sentences

    Summary
    Epicardial adipose tissue thickness significantly decreased in both semaglutide and dulaglutide groups (P < 0.001) after 12 weeks, accounting for a 20% reduction.
    2 context sentences
    Summary · context
    We performed a 12-week, controlled, parallel study in 80 subjects with T2DM and obesity.
    Summary · context
    Patients received either semaglutide, up to 1 mg subcutaneous (sc) weekly, or dulaglutide, up to 1.5 mg sc weekly, as the standard of care in addition to their usual medication regimen.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with T2DM and obesity, epicardial fat thickness decreased from baseline after 12 weeks of dulaglutide, a reduction of about 20% reported for the semaglutide and dulaglutide groups together.

    In plain wordsIn patients with diabetes and obesity, fat thickness around the heart fell from baseline with dulaglutide, about 20% across both drug groups.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseEpicardial fat thickness
    Study

    n: not reported in source

    Outcome group
    Body composition · Cardiovascular
    Studied dose
    up to 1.5 mg weekly · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    Epicardial adipose tissue thickness reduction
    20%
    semaglutide and dulaglutide groups, as reported

    Source sentences

    Summary
    Epicardial adipose tissue thickness significantly decreased in both semaglutide and dulaglutide groups (P < 0.001) after 12 weeks, accounting for a 20% reduction.
    2 context sentences
    Summary · context
    We performed a 12-week, controlled, parallel study in 80 subjects with T2DM and obesity.
    Summary · context
    Patients received either semaglutide, up to 1 mg subcutaneous (sc) weekly, or dulaglutide, up to 1.5 mg sc weekly, as the standard of care in addition to their usual medication regimen.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with T2DM and obesity, epicardial fat thickness reduction was greater with higher-dose semaglutide.

    In plain wordsIn patients with diabetes and obesity, higher-dose semaglutide reduced heart fat thickness more than lower doses.

    Peptide
    Semaglutide
    Outcome
    DecreaseEpicardial fat thickness by dose
    Study

    n: not reported in source

    Comparator
    Lower semaglutide doses
    Outcome group
    Body composition · Cardiovascular
    Studied dose
    1 mg · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Epicardial adipose tissue thickness reduction was significantly greater (P < 0.01) with the higher doses of semaglutide (1 mg) and dulaglutide (1.5 mg), respectively.
    2 context sentences
    Summary · context
    We performed a 12-week, controlled, parallel study in 80 subjects with T2DM and obesity.
    Summary · context
    Patients received either semaglutide, up to 1 mg subcutaneous (sc) weekly, or dulaglutide, up to 1.5 mg sc weekly, as the standard of care in addition to their usual medication regimen.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with T2DM and obesity, epicardial fat thickness reduction was greater with higher-dose dulaglutide.

    In plain wordsIn patients with diabetes and obesity, higher-dose dulaglutide reduced heart fat thickness more than lower doses.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseEpicardial fat thickness by dose
    Study

    n: not reported in source

    Comparator
    Lower dulaglutide doses
    Outcome group
    Body composition · Cardiovascular
    Studied dose
    1.5 mg · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Epicardial adipose tissue thickness reduction was significantly greater (P < 0.01) with the higher doses of semaglutide (1 mg) and dulaglutide (1.5 mg), respectively.
    2 context sentences
    Summary · context
    We performed a 12-week, controlled, parallel study in 80 subjects with T2DM and obesity.
    Summary · context
    Patients received either semaglutide, up to 1 mg subcutaneous (sc) weekly, or dulaglutide, up to 1.5 mg sc weekly, as the standard of care in addition to their usual medication regimen.

Studies that did not test the peptide alone4

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 05HumanNot a test of Semaglutide aloneNon-randomized trialEfficacy outcome

    In patients with T2DM and obesity, BMI improved nonsignificantly in all groups, including semaglutide and controls.

    In plain wordsBMI improved without statistical significance in all patient groups, including semaglutide and controls.

    Peptide
    Semaglutide
    Outcome
    No significant changeBMI change across all groups
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Body mass index (BMI) and HbA1c improved in all groups without reaching statistical significance.
    3 context sentences
    Summary · context
    Twenty subjects with T2DM and obesity were started on metformin and a diet and served as the control group.
    Summary · context
    We performed a 12-week, controlled, parallel study in 80 subjects with T2DM and obesity.
    Summary · context
    Patients received either semaglutide, up to 1 mg subcutaneous (sc) weekly, or dulaglutide, up to 1.5 mg sc weekly, as the standard of care in addition to their usual medication regimen.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 06HumanNot a test of Dulaglutide (Trulicity) aloneNon-randomized trialEfficacy outcome

    In patients with T2DM and obesity, BMI improved nonsignificantly in all groups, including dulaglutide and controls.

    In plain wordsBMI improved without statistical significance in all patient groups, including dulaglutide and controls.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeBMI change across all groups
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Body mass index (BMI) and HbA1c improved in all groups without reaching statistical significance.
    3 context sentences
    Summary · context
    Twenty subjects with T2DM and obesity were started on metformin and a diet and served as the control group.
    Summary · context
    We performed a 12-week, controlled, parallel study in 80 subjects with T2DM and obesity.
    Summary · context
    Patients received either semaglutide, up to 1 mg subcutaneous (sc) weekly, or dulaglutide, up to 1.5 mg sc weekly, as the standard of care in addition to their usual medication regimen.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  3. 07HumanNot a test of Semaglutide aloneNon-randomized trialEfficacy outcome

    In patients with T2DM and obesity, HbA1c improved nonsignificantly in all groups, including semaglutide and controls.

    In plain wordsHbA1c improved without statistical significance in all patient groups, including semaglutide and controls.

    Peptide
    Semaglutide
    Outcome
    No significant changeHbA1c change across all groups
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Body mass index (BMI) and HbA1c improved in all groups without reaching statistical significance.
    3 context sentences
    Summary · context
    Twenty subjects with T2DM and obesity were started on metformin and a diet and served as the control group.
    Summary · context
    We performed a 12-week, controlled, parallel study in 80 subjects with T2DM and obesity.
    Summary · context
    Patients received either semaglutide, up to 1 mg subcutaneous (sc) weekly, or dulaglutide, up to 1.5 mg sc weekly, as the standard of care in addition to their usual medication regimen.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 08HumanNot a test of Dulaglutide (Trulicity) aloneNon-randomized trialEfficacy outcome

    In patients with T2DM and obesity, HbA1c improved nonsignificantly in all groups, including dulaglutide and controls.

    In plain wordsHbA1c improved without statistical significance in all patient groups, including dulaglutide and controls.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeHbA1c change across all groups
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Body mass index (BMI) and HbA1c improved in all groups without reaching statistical significance.
    3 context sentences
    Summary · context
    Twenty subjects with T2DM and obesity were started on metformin and a diet and served as the control group.
    Summary · context
    We performed a 12-week, controlled, parallel study in 80 subjects with T2DM and obesity.
    Summary · context
    Patients received either semaglutide, up to 1 mg subcutaneous (sc) weekly, or dulaglutide, up to 1.5 mg sc weekly, as the standard of care in addition to their usual medication regimen.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Versions 2 to 3

    21 Oct 2026, 18:59 UTC

    The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.